XML 117 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2018
Summary Of Significant Accounting Policies  
Disaggregation of revenue
    Nine-months Ended  
    September, 30  
    2018     2017  
CellerateRX Powder   $ 5,249,059     $ 4,083,068  
CellerateRX Gel     355,472       373,344  
HemaQuell     35,021       -  
Royalty revenue     150,750       150,750  
Total Revenue   $ 5,790,302     $ 4,607,162